WO1997031655A3 - Modified cytokines for therapeutic use - Google Patents
Modified cytokines for therapeutic use Download PDFInfo
- Publication number
- WO1997031655A3 WO1997031655A3 PCT/EP1997/000704 EP9700704W WO9731655A3 WO 1997031655 A3 WO1997031655 A3 WO 1997031655A3 EP 9700704 W EP9700704 W EP 9700704W WO 9731655 A3 WO9731655 A3 WO 9731655A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- component
- cytokines
- therapeutic use
- modified cytokines
- modified
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
- A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97903285A EP0885015A2 (en) | 1996-02-27 | 1997-02-14 | Modified cytokines for therapeutic use |
AU17694/97A AU1769497A (en) | 1996-02-27 | 1997-02-14 | Modified cytokines for therapeutic use |
JP9530545A JP2000506835A (en) | 1996-02-27 | 1997-02-14 | Modified cytokines for therapy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT96MI000358A IT1282692B1 (en) | 1996-02-27 | 1996-02-27 | CYTOKINES MODIFIED FOR THERAPY USE |
ITMI96A000358 | 1996-02-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1997031655A2 WO1997031655A2 (en) | 1997-09-04 |
WO1997031655A3 true WO1997031655A3 (en) | 1997-11-13 |
Family
ID=11373397
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1997/000704 WO1997031655A2 (en) | 1996-02-27 | 1997-02-14 | Modified cytokines for therapeutic use |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0885015A2 (en) |
JP (1) | JP2000506835A (en) |
AU (1) | AU1769497A (en) |
CA (1) | CA2247308A1 (en) |
IT (1) | IT1282692B1 (en) |
WO (1) | WO1997031655A2 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000012554A1 (en) * | 1998-08-28 | 2000-03-09 | Commissariat A L'energie Atomique | Method for marked chemokine synthesis, marked chemokine and analysis kit |
FR2783528A1 (en) * | 1998-08-28 | 2000-03-24 | Commissariat Energie Atomique | Synthesis of labeled chemokine, useful for developing anti-inflammatory and antiviral agents uses conventional peptide synthesis with label attached to sidechain at predetermined position |
DE19845798A1 (en) * | 1998-09-29 | 2000-04-13 | Schering Ag | Use of neoangiogenesis markers for diagnosis and therapy of tumors, agents containing them, and methods for their production |
CA2713137C (en) * | 2008-01-25 | 2017-10-24 | Hadasit Medical Research Services And Development Ltd. | Targeting of innate immune response to tumor site |
EA201892619A1 (en) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | IMMUNOCONJUGATES CONTAINING INTERLEUKIN-2 MUTANT POLYPETIPS |
TW202214691A (en) | 2014-03-21 | 2022-04-16 | 美商艾伯維有限公司 | Anti-egfr antibodies and antibody drug conjugates |
CN109563167A (en) | 2016-06-08 | 2019-04-02 | 艾伯维公司 | Anti- B7-H3 antibody and antibody drug conjugates |
WO2017214456A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
WO2017214335A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
CA3027103A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
US11932694B2 (en) | 2017-04-19 | 2024-03-19 | Bluefin Biomedicine, Inc. | Anti-VTCN1 antibodies and antibody drug conjugates |
UY39610A (en) | 2021-01-20 | 2022-08-31 | Abbvie Inc | ANTI-EGFR ANTIBODY-DRUG CONJUGATES |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994018325A1 (en) * | 1993-02-03 | 1994-08-18 | N.V. Innogenetics S.A. | Tnf-alpha muteins and a process for preparing them |
WO1995014493A1 (en) * | 1993-11-23 | 1995-06-01 | Neorx Corporation | Three-step pretargeting methods and compounds |
WO1995015979A1 (en) * | 1993-12-07 | 1995-06-15 | Neorx Corporation | Pretargeting methods and compounds |
-
1996
- 1996-02-27 IT IT96MI000358A patent/IT1282692B1/en active IP Right Grant
-
1997
- 1997-02-14 WO PCT/EP1997/000704 patent/WO1997031655A2/en not_active Application Discontinuation
- 1997-02-14 CA CA002247308A patent/CA2247308A1/en not_active Abandoned
- 1997-02-14 AU AU17694/97A patent/AU1769497A/en not_active Abandoned
- 1997-02-14 EP EP97903285A patent/EP0885015A2/en not_active Withdrawn
- 1997-02-14 JP JP9530545A patent/JP2000506835A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994018325A1 (en) * | 1993-02-03 | 1994-08-18 | N.V. Innogenetics S.A. | Tnf-alpha muteins and a process for preparing them |
WO1995014493A1 (en) * | 1993-11-23 | 1995-06-01 | Neorx Corporation | Three-step pretargeting methods and compounds |
WO1995015979A1 (en) * | 1993-12-07 | 1995-06-15 | Neorx Corporation | Pretargeting methods and compounds |
Non-Patent Citations (6)
Title |
---|
6TH INT. TUMOR NECROSIS FACTOR CONGRESS, 8 May 1996 (1996-05-08) - 12 May 1996 (1996-05-12), RHODES (GREECE) * |
CHEMICAL ABSTRACTS, vol. 124, no. 11, 11 March 1996, Columbus, Ohio, US; abstract no. 142954, VODYANIK, M. A. ET AL: "Flow cytometric detection of two types of tumor necrosis factor alpha (TNF) receptors by biotinamidocaproyl-TNF in human tumor cells" XP002040778 * |
CORTI A. ET AL.: "TUMOR CELL TARGETING WITH ANTIBODY-AVIDIN COMPLEXES AND BIOTINYLATED TNF.", EUROPEAN CYTOKINE NETWORK, vol. 7, no. 2, 1996, pages 289 * |
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; XP002040779 * |
EKSP. ONKOL. (1995), 17(1), 11-17 CODEN: EKSODD;ISSN: 0204-3564, 1995 * |
STONE D. ET AL.: "Pretargeting as a delivery system for tumor-specific localization of TNF-alpha.", PROCEEDINGS OF THE AMERICAN ASSOC. FOR CANCER RES., vol. 37, March 1996 (1996-03-01), pages 484, XP002040787 * |
Also Published As
Publication number | Publication date |
---|---|
CA2247308A1 (en) | 1997-09-04 |
AU1769497A (en) | 1997-09-16 |
IT1282692B1 (en) | 1998-03-31 |
JP2000506835A (en) | 2000-06-06 |
WO1997031655A2 (en) | 1997-09-04 |
EP0885015A2 (en) | 1998-12-23 |
ITMI960358A0 (en) | 1996-02-27 |
ITMI960358A1 (en) | 1997-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1997031655A3 (en) | Modified cytokines for therapeutic use | |
EP1958965A3 (en) | Agonist antibodies to a musk receptor, and their therapeutic uses | |
EP1752465A3 (en) | Linear VH-CH1-VH-CH1 heavy chain antibody fragment | |
EP2371962A3 (en) | Receptor activator of NF-KAPPA B, receptor is member of TNF receptor superfamily | |
ZA9610535B (en) | Antagonists of gonadotropin releasing hormone. | |
CA2114015A1 (en) | Recombinant antibodies for human therapy | |
AU2329897A (en) | Monoclonal antibodies specific for the platelet derived growth factor beta receptor and methods of use thereof | |
AU6306398A (en) | Single and double chain antibodies to the egf receptor, derivatives thereof and their use | |
AU3633997A (en) | Chemokine receptor antagonists | |
AU2721797A (en) | Artificial antibodies to corticosteroids prepared by molecular imprinting | |
EP1162264A3 (en) | Chimeric hormone receptor | |
DK0669979T3 (en) | C-C CKR-1, chemokine receptor | |
EA199900331A1 (en) | PREPARATION FROM COATED PARTICLES | |
AU4552497A (en) | Novel carboxylic acid derivatives, their preparation and use as mixed eta/etb receptor antagonists | |
AU1230795A (en) | Adhesion receptor antagonists | |
AU5641798A (en) | Artificial antibodies, method of producing the same and use thereof | |
AU2093297A (en) | Use of 5-ht1a receptor antagonists for the treatment of urinary incontinence | |
EP0345056A3 (en) | Improvements in and relating to serotonin antagonists | |
AU5514396A (en) | Cyclic pentapeptide lh-rh receptor antagonists | |
AU7289196A (en) | Combination of ltd, receptor antagonists with glucocorticosteroids | |
MX9708557A (en) | New pharmacological use of aii-receptor antagonists. | |
AU4446296A (en) | Adhesion receptor antagonists | |
AU3221793A (en) | Factor x-derived polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting inflammation | |
WO1995022609A3 (en) | Human glutamate receptor proteins | |
AU6446194A (en) | Monoclonal antibodies specific for fibroblast growth factor receptors, immunotoxins, and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2247308 Country of ref document: CA Ref country code: CA Ref document number: 2247308 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997903285 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1997903285 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997903285 Country of ref document: EP |